bullish
Quiddity JPX-Nikkei 400 Rebal 2025: End-Oct 2024 Ranks
297 Views30 Oct 2024 15:05
The HIGH and MED conviction potential ADDs could outperform the HIGH and MED conviction potential DELs over the next few months.
What is covered in the Full Insight:
- Introduction to JPX-Nikkei 400
- Methodology
- Determination of Constituents
- Quiddity Leaderboard
- Conclusion
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Quiddity Leaderboard F100/250 Dec 24: LONGs Up 10% Vs Index in a Month; Time for New Trade27 Nov 2024
- Quiddity Leaderboard TDIV Dec 24: Final Expectations; US$1.68bn One-Way; +17% Gain from Last Trade26 Nov 2024
- Quiddity Leaderboard CSI Medical Dec 24: Final Rankings; Exp ADDs Underperforming Exp DELs04 Nov 2024
- Quiddity Leaderboard ASX Dec 24: Clarity Pharma and Resolute Mining Competing for ASX 200 Spot21 Oct 2024
- TOPIX Inclusions: Who Is Ready (Oct 2024)07 Oct 2024
- Quiddity JPX-Nikkei 400 Rebal 2025: End-Sep 2024 Ranks30 Sep 2024
x